Literature DB >> 25063220

Role of reactive oxygen species in angiotensin II: induced receptor activator of nuclear factor-κB ligand expression in mouse osteoblastic cells.

Yanqiu Zhang1, Yongtao Zhang, Jianqiang Kou, Chunsheng Wang, Kunzheng Wang.   

Abstract

Angiotensin II (Ang II) has been shown to induce receptor activator of nuclear factor-κB ligand (RANKL) expression in osteoblasts associated with its effect on reactive oxygen species (ROS) production. The objective of the present study was to investigate the potential pathways by which Ang II induces RANKL expression and the role of ROS in Ang II-induced RANKL expression in mouse osteoblastic MC3T3-E1 cells. Treatment with Ang IIinduced RANKL expression in a dose- and time-dependent manner in osteoblasts, which was attenuated by pre-treatment with an AT1 receptor antagonist (olmesartan), ROS scavenger (N-acetylcysteine, NAC), or the ERK inhibitor (U0126), but not with AT2R antagonist (PD123319). Furthermore, Ang II enhanced AT1R and NAD(P)H oxidase (NOX) p22(phox) and p67(phox) expression and activity in osteoblasts. In addition, Ang II promoted ROS production, which was mitigated by pre-treatment with olmesartan or a NOX inhibitor (diphenyleneiodonium, DPI), but not with PD1123319 or U0126, in osteoblasts. Moreover, Ang II enhanced the ERK1/2 phosphorylation, which was abrogated by pre-treatment with olmesartan, NAC, DPI, or U0126 in osteoblasts. These results suggest that Ang II, through its AT1R, enhanced NOX activity and ROS production, and activated the ERK pathway to up-regulate RANKL expression in osteoblasts in vitro.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25063220     DOI: 10.1007/s11010-014-2160-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  22 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells.

Authors:  Chiaki Tanifuji; Yusuke Suzuki; Wong Mu Geot; Satoshi Horikoshi; Takeshi Sugaya; Marta Ruiz-Ortega; Jesus Egido; Yasuhiko Tomino
Journal:  Antioxid Redox Signal       Date:  2005 Sep-Oct       Impact factor: 8.401

Review 3.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

Review 4.  The role of IL-6 type cytokines and their receptors in bone.

Authors:  S C Manolagas
Journal:  Ann N Y Acad Sci       Date:  1998-05-01       Impact factor: 5.691

5.  Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.

Authors:  R Hatton; M Stimpel; T J Chambers
Journal:  J Endocrinol       Date:  1997-01       Impact factor: 4.286

6.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

7.  Angiotensin II stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling.

Authors:  Q Pan; X-H Yang; Y-X Cheng
Journal:  Braz J Med Biol Res       Date:  2009-06       Impact factor: 2.590

8.  Protective effects of estradiol on ethanol-induced bone loss involve inhibition of reactive oxygen species generation in osteoblasts and downstream activation of the extracellular signal-regulated kinase/signal transducer and activator of transcription 3/receptor activator of nuclear factor-kappaB ligand signaling cascade.

Authors:  Jin-Ran Chen; Kartik Shankar; Shanmugam Nagarajan; Thomas M Badger; Martin J J Ronis
Journal:  J Pharmacol Exp Ther       Date:  2007-10-04       Impact factor: 4.030

9.  Role of reactive oxygen species (ROS) in angiotensin II-induced stimulation of the cardiac Na+/HCO3- cotransport.

Authors:  Verónica C De Giusti; Carolina D Garciarena; Ernesto A Aiello
Journal:  J Mol Cell Cardiol       Date:  2009-07-30       Impact factor: 5.000

10.  Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix.

Authors:  G van der Pluijm; W Most; L van der Wee-Pals; H de Groot; S Papapoulos; C Löwik
Journal:  Endocrinology       Date:  1991-09       Impact factor: 4.736

View more
  4 in total

1.  Angiotensin II upregulates RANKL/NFATC1 expression in synovial cells from patients with rheumatoid arthritis through the ERK1/2 and JNK pathways.

Authors:  Zhiping Zhao; Yongtao Zhang; Changyao Wang; Xiangyu Wang; Yingzhen Wang; Haining Zhang
Journal:  J Orthop Surg Res       Date:  2021-05-05       Impact factor: 2.359

2.  Chloroquine ameliorates bone loss induced by d-galactose in male rats via inhibition of ERK associated osteoclastogenesis and antioxidant effect.

Authors:  Mohamed A Aziz Mahmoud; Dalia O Saleh; Marwa M Safar; Azza M Agha; Mahmoud M Khattab
Journal:  Toxicol Rep       Date:  2021-02-15

3.  The Embryonic Chick Femur Organotypic Model as a Tool to Analyze the Angiotensin II Axis on Bone Tissue.

Authors:  Thais Francini Garbieri; Victor Martin; Carlos Ferreira Santos; Pedro de Sousa Gomes; Maria Helena Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16

4.  Functional Local Renin-Angiotensin System in Human and Rat Periodontal Tissue.

Authors:  Carlos F Santos; Ana C Morandini; Thiago J Dionísio; Flávio A Faria; Marta C Lima; Caio M Figueiredo; Bella L Colombini-Ishikiriama; Carla R Sipert; Rubens P Maciel; Ana P Akashi; Gabriela P Souza; Gustavo P Garlet; Camila O Rodini; Sandra L Amaral; Christiane Becari; Maria C Salgado; Eduardo B Oliveira; Isaac Matus; Daniela N Didier; Andrew S Greene
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.